ABSTRACT
Enzyme Linked Immunosorbent Assay (ELISA) and Westernblot were employed to analyze sera collected from one thousand and fifty (1050) patients who tested HIV positive type-1. Out of this, 95 (9.1%) of the patients were less than 2 years old, 102 (10.0%) were aged between 2-15 years old while 813 (77.4%) were aged above 15 years. For any age group, the ratio of male to female was 1:1 except that there was excess of males below 5 years. There were four (4) most frequent signs and symptoms observed. These were loss of weight or malnutrition, generalized lymphadenopathy, chronic watery diarrhoea and chronic chest infections. Loss of weight was recorded in 65.0% of the seropositive patients in all age groups. Generalized lymphadenopathy was seen in 35.0% of all the age groups but was most frequent in 36.1% of those less than 2 years. Chronic watery diarrhoea (42.8%) was frequent in patients less than 2 years and less frequent in 18.0% of older children between 1-15 years. Chronic chest infections were least frequent in 25.0% of adults above 15 years old and highest frequency was observed in 53.0%, children less than 2 years. Forty patients had incomplete documentations and children of pediatric ages had acutely overt clinical manifestation of HIV (1&11) attributable to undeveloped immune competence.
Subject(s)
Adolescent , Adult , Blotting, Western/methods , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay/methods , Female , HIV Antibodies/blood , HIV Infections/blood , HIV Seropositivity/complications , HIV-1/immunology , Humans , Infant , Male , Middle Aged , Nigeria/epidemiology , Population SurveillanceABSTRACT
The Nigerian Expanded Programme on Immunization (EPI) was assessed with particular reference to measles immunization. Of 150 children who received measles vaccine at the Institute of Child Health, University of Ibadan, Nigeria, 82 (54.7%) seroconverted. The immune response was directly related to the titre of the vaccines used. Vaccines whose titres were 10(-1) to 10(1.7) stimulated immune responses in 0-25% of vaccinees, those with titres in the range 10(-2.1) to 10(-2.5) stimulated responses in 12-47.6%, while those with titres of 10(-2.7) to 10(-3.4) stimulated responses in 87.5-100% of vaccinees. Only one of the vaccines used had a titre that met the minimum WHO required standard of log 10(-3) TCID50 at the point of vaccination